OTLK — Outlook Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649989 ·
Last close
$0.61
Market Cap
$147.79M
52W High
$1.88
52W Low
$0.38
ADV30
22,368,468
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 127,439 | -21,888 | -14,026,987 | -4,453,081 | 21,892,406 | 7,748,226 | 50,887,177 |
| Dec 2025 | -1,207,833 | -1,237,459 | -13,483,952 | -23,058,135 | 18,238,574 | 8,677,424 | 56,788,039 |
| Sep 2025 | -91,787 | -1,008,302 | -17,314,606 | -13,292,769 | 18,584,183 | 8,083,085 | 50,771,844 |
| Jun 2025 | 1,505,322 | 1,065,507 | -15,748,680 | -20,152,502 | 22,391,540 | 8,900,814 | 59,581,265 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,045,522
Investing CF
—
Financing CF
$47,237,435
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.48
As of
2026-08-23
Balance + Analyst (yfinance extras)
Retained Earnings
$-633,220,979
Inventory
$3,344,242
Receivables
$2,719,828
ST Investments
—
EBIT TTM
$-62,197,332
Pretax Income TTM
$-62,511,116
Interest Exp TTM
$313,507
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$-1,163,481
EBITDA
$-55,531,736
Free Cash Flow
$-37,357,632
Enterprise Value
$155,448,640
Total Cash
$11,242,068
Total Debt
$18,431,144
Shares Out
242,672,554
Trailing EPS
$-0.70
Book Value
$-0.60
ROE
—
ROA
-143.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 1,413,535 | -67,061,666 | -62,424,863 | 18,584,183 | 50,771,844 | — | -51,829,437 |
| Sep 2024 | 0 | -71,703,235 | -75,366,714 | 28,823,154 | 101,899,664 | — | -68,793,858 |
| Sep 2023 | 0 | -53,126,382 | -58,982,668 | 32,300,601 | 46,738,378 | — | -42,973,398 |
| Sep 2022 | 0 | -63,070,753 | -66,052,264 | 28,527,751 | 19,791,180 | — | -56,674,559 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.14
Max Pain — expiry 2027-01-15
max pain strike: $0.50 · spot: $0.66 · call oi: 16,257 · put oi: 1,180
Expected Move to 2027-01-15:
±$0.45
(68.16%) —
implied range
$0.21 –
$1.11
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc. | $151.29M | $0.67 | — |
| LENZ | LENZ Therapeutics, Inc. | $144.22M | $4.59 | — |
| MOLN | MOLECULAR PARTNERS AG | $165.05M | $4.40 | — |
| CRBU | Caribou Biosciences, Inc. | $175.82M | $1.64 | — |
| VXRT | Vaxart, Inc. | $123.82M | $0.51 | — |
News headlines (Yahoo Finance, 1h cache)
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
2026-08-15 06:12 · Yahoo
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
2026-08-14 11:15 · Yahoo
Why Did OTLK Stock Crash In Pre-Market Today?
2026-08-13 10:31 · Yahoo
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
2026-08-12 20:01 · Yahoo
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
2026-08-06 12:45 · Yahoo
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
2026-08-03 14:58 · Yahoo
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
2026-08-17 14:00 · Yahoo
Oncobiologics Q3 Earnings Call Highlights
2026-08-14 15:04 · Yahoo
Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-08-14 12:30 · Yahoo
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
2026-08-14 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.